Dr Lal PathLabs in Focus After SN Genelab Acquisition

Dr Lal PathLabs is in focus on Sept 25, 2026 after approving a 70% stake acquisition in SN Genelab. Key levels: ₹1,990 resistance and ₹1,855 support. Dr Lal PathLabs

is in focus today following a key corporate development. The company’s board has approved the acquisition of a 70% stake in SN Genelab from its existing shareholders for up to ₹168 crore. Following completion, SN Genelab will become a subsidiary of Dr Lal PathLabs. The transaction is expected to be completed by 30 November 2026. The stock showed relative resilience in the previous session, closing around 2% higher at ₹1,961.30, despite the broader sell-off across major indices. This price action keeps the stock on the radar for traders and investors today. From a technical perspective, ₹1,990 is the immediate resistance level to watch. A sustained move above this zone could bring the 52-week high of ₹2,038 into focus. On the downside, ₹1,855 remains an important support level. Traders may watch price action around these levels alongside volumes and broader market sentiment. Overall, the acquisition announcement and the stock’s relative strength make Dr Lal PathLabs one of the stocks to watch today. Disclosure: I do not hold any position or have any financial interest in the mentioned stock.